Sandra Silberman, MD, PhD | Duke University
Sandra Silberman, M.D., Ph.D. was appointed Chief Medical Officer of New Products at Moleculin Biotech, Inc. on November 8, 2017, with oversight of several drugs developed at MD Anderson Cancer Center.
Prior to that, Dr. Silberman was Vice President and Global Head of Translational Medicine in the newly formed Innovation division of Quintiles, overseeing drug development, novel technologies, and original clinical study designs to help establish partnerships with the pharmaceutical and biotechnology industries.
She also previously served as President and Chief Medical Officer of Archer Biosciences, implementing a global clinical trial development strategy for a proprietary oncology drug in Glioblastoma Multiforme. Dr. Silberman also served as the Chief Medical Officer of Heat Biologics, Inc. in 2013, for which she helped the company acquire funding and get listed on the NASDAQ exchange. Dr. Silberman previously served as Senior Director for Novartis Clinical Research, where she led the global development of Gleevec(TM), the first targeted therapy for chronic myelogenous leukemia (CML), and for which all additional registrations for Gleevec were based on her clinical trial designs. Dr. Silberman subsequently joined Eisai Medical Research as the Global Therapeutic Area Head in Oncology, where she led the advancement of five original compounds into clinical programs, and one through Phase III development for regulatory approval.
Dr. Silberman began her career in clinical development at Pfizer Inc., where she initiated the first programs in clinical oncology at that company, participated in the preclinical advancement of novel oncology drug candidates and oversaw the introduction of TarcevaTM into clinical trials.
She has been an Independent Industry Consultant for several companies, including Bristol-Myers Squibb, AstraZeneca, Imclone, Roche and several biotechnology companies in various oncology and immunology programs spanning preclinical research and IND applications through NDA submission. She has been a Member of the Clinical Advisory Board at Trovagene, Inc. since April 13, 2017. She was a Member of the Scientific Advisory Board at Moleculin Biotech, Inc. since January 19, 2017, prior to serving as their CMO. She served as a Member of the Scientific Advisory Board at Heat Biologics Inc. She served as a Member of the Scientific Advisory Board at Bering Exploration, Inc. (formerly, Oncolin Therapeutics Inc.), since March 2008.
Dr. Silberman is a world-renowned oncologist. She has numerous publications and is named on several patents in the cancer drug development field, including novel anti-tubulin agents for advanced solid tumors as well as targeted tyrosine kinase inhibitors (TKI). She has authored more than 50 abstracts and peer-reviewed papers and is a named inventor on several patents in the cancer drug development field.
She completed a fellowship in Hematology/Oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute in Boston and was an Instructor in Medicine at Harvard Medical School as well as an attending physician at Yale University Hospital.
She is board-certified in Internal Medicine and Hematology/Oncology. Dr. Silberman has BA, Sc.M., and PhD (tumor immunology) degrees from The Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively. She has an MD from Cornell University Medical College. She is currently an attending physician for the Duke Hematology/Oncology Fellowship program in Durham, NC.